A shorter symptom-onset to remdesivir treatment (SORT) inter
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Remdesivir is the current recommended anti-viral treatment in moderate-to-severe COVID-19. However, data on impact of timing of therapy, efficacy, and safety are limited. We evaluated the impact of timing of remdesivir initiation (symptom-onset to remdesivir treatment [SORT] interval) on in-hospital all-cause mortality in patients with moderate-to-severe COVID-19.

This retrospective study was conducted between June 25 and October 3, 2020, at a tertiary care dedicated COVID center in India. Patients with moderate-to-severe COVID-19 (moderate: SpO2?less than?94%; severe: SpO2?less than 90%) were included. The main outcome was impact of SORT interval on in-hospital all-cause mortality. Subgroups were formed and analyzed based on SORT interval.

Results:
-- Of 350 patients treated with remdesivir, 346 were included in final analysis.

-- Overall, 76 (22.0%) patients died (moderate: 3 [2.8%], severe: 73 [30.8%]).

-- All-cause mortality was significantly lower in patients with SORT interval less than 9 days (n?=?260) vs SORT interval more than 9 days.

-- The odds of death were significantly lower in patients with SORT interval less than 9 days vs more than 9 days.

Conclusively, remdesivir initiation less than 9 days from symptom-onset was associated with mortality benefit, defining a treatment window and reinforcing the need for appropriately-timed remdesivir in moderate-to-severe COVID-19.

Source: https://www.ijidonline.com/article/S1201-9712(21)00178-8/fulltext?rss=yes
Like
Comment
Share